NCT03931551: Olaparib + Trastuzumab in HER2+ Breast Cancer Susceptibility Gene (BRCA) Mutated or Homologous Recombination Deficient (HRD) Advanced Breast Cancer

NCT03931551
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Therapeutic Antibody, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must only be HER2+, BRCA+ is not required; Patients must have progressed on HER2-directed therapy with no more than 3 prior regimens of chemotherapy and/or trastuzumab-lapatinib in advanced scenario, & at least one regimen of chemotherapy including trastuzumab
Exclusions: Patients with symptomatic uncontrolled brain metastases.- see trial for details; Patients that have received any PARP inhibitors for any reason; Patients that have received carboplatin or other platinum containing compounds in the last 12 months prior to entry to the study
https://ClinicalTrials.gov/show/NCT03931551

Comments are closed.

Up ↑